Journal of Blood Medicine (Oct 2019)
Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives
Abstract
Shayna Sarosiek, Vaishali Sanchorawala Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA, USACorrespondence: Shayna Sarosiek; Vaishali SanchorawalaAmyloidosis Center, Boston University School of Medicine and Boston Medical Center, 820 Harrison Ave, FGH Building – 1, Boston, MA 02118, USATel +1617-637-7011Fax +1617-414-1831Email [email protected]; [email protected]: Systemic immunoglobulin light chain (AL) amyloidosis is a disorder characterized by the production of clonal serum free light chains that misfold, aggregate, and deposit in vital organs. Treatment of this disease is typically targeted at the abnormal plasma cell clone in the bone marrow which is the source of the amyloidogenic light chain. First-line therapies in this disease are well established, but in the relapsed or refractory setting, there are many treatment options, including immunomodulatory agents, proteasome inhibitors, alkylating agents, and monoclonal antibodies. Decisions regarding treatment choice should be made by a multidisciplinary team with consideration of the patient’s functional status, disease stage, degree of organ dysfunction, and potential treatment toxicities. Herein we review the current treatment options available for patients with relapsed or refractory AL amyloidosis.Keywords: AL amyloidosis, light chain amyloidosis, relapsed, refractory
